Clinical Trial Update: 3BNC117 and 10-1074 in ART-treated Individuals [Phase 1]

View source ↗

Summary

An update on a Phase 1 trial evaluating the HIV broadly neutralizing antibodies 3BNC117 and 10-1074 in ART-treated individuals; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• 10-1074
• 3BNC117

Snippet

Sponsor: Rockefeller University | Conditions: Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED